EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design

Jörg H W Distler, Shervin Assassi, Armando Gabrielli, Yannick Allanore, Lorinda Chung, Maurizio Cutolo, Francesco Del Galdo, Jeska K De Vries-Bouwstra, Robyn T Domsic, Muriel Elhai, Tracy Frech, Monique Hinchcliff und 24 weitere

Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2099-2106

DOI: 10.1016/j.ard.2026.08.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Jörg H W Distler und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospit…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Drug Development. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic sclerosis (SSc) is a multifaceted systemic autoimmune disease, characterised by the interplay of vascular alterations, immune dysregulation, and fibrosis. The molecular changes and the clinical presentation of SSc are highly heterogeneous and vary considerably between individual patients. This heterogeneity has hampered efforts to reach a unified and pragmatic definition of disease modification in SSc. Using a consensus approach among SSc experts, the authors seek to identify current challenges in defining SSc disease modification. The definition of disease modification in SSc requires a nuanced approach that considers molecular, mechanistic, and clinical aspects. Disease-modifying treatments in SSc should target core pathways or cells rather than regulatory mechanisms. Disease-modifying treatments should show sustained effects on disease activity and prevent progression of damage across organs, manifestations, disease stages, and disease endotypes. The complex and variable nature of SSc needs to be reflected in preclinical drug development efforts and clinical trial designs to demonstrate disease-modifying effects of drug candidates for SSc. We herein provide a first framework for the definition of disease modification of vascular, inflammatory, and fibrotic domains in SSc. Advances in our understanding of the cellular and molecular mechanisms driving the progression of SSc will enable further refinement of the definition of disease modification and guide optimal preclinical modelling and innovative clinical trial design in future efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicDrug DevelopmentHumansDisease ProgressionResearch DesignFibrosisClinical Trials as Topic

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany. Electro…
  • Department of Internal Medicine, Division of Rheumatology, UTHealth Houston, Houston, TX, USA.
  • Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany; Foundat…
  • Department of Rheumatology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Université Paris Cité, Paris, France.
  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA; Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA.
  • Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Liguria, Italy; Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal…

Förderung

  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Distler, J. H. W., Assassi, S., Gabrielli, A., Allanore, Y., Chung, L., Cutolo, M., Galdo, F. D., De Vries-Bouwstra, J. K., Domsic, R. T., Elhai, M., Frech, T., Hinchcliff, M., Homey, B., Khanna, D., Krieg, T., Kuwana, M., Lescoat, A., Low, A. H. L., Matucci-Cerinic, M., …, & Distler, O. (2026). Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design. Annals of the Rheumatic Diseases, 85(11), 2099-2106. https://doi.org/10.1016/j.ard.2026.08.006

Vancouver

Distler JHW, Assassi S, Gabrielli A, Allanore Y, Chung L, Cutolo M, et al. Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design. Annals of the Rheumatic Diseases. 2026;85(11):2099-2106. doi:10.1016/j.ard.2026.08.006

BibTeX
@article{Distler2026,
  author = {Distler, Jörg H W and Assassi, Shervin and Gabrielli, Armando and Allanore, Yannick and Chung, Lorinda and Cutolo, Maurizio and Galdo, Francesco Del and De Vries-Bouwstra, Jeska K and Domsic, Robyn T and Elhai, Muriel and Frech, Tracy and Hinchcliff, Monique and Homey, Bernhard and Khanna, Dinesh and Krieg, Thomas and Kuwana, Masataka and Lescoat, Alain and Low, Andrea H L and Matucci-Cerinic, Marco and McMahan, Zsuzsanna H and Molitor, Jerry A and Mouthon, Luc and Nikpour, Mandana and Riemekasten, Gabriela and Spierings, Julia and Truchetet, Marie-Elise and Smith, Vanessa and Varga, John and Volkmann, Elizabeth and Vonk, Madelon C and Wang, Jiucun and Xu, Dong and Zhu, Honglin and Hoffmann-Vold, Anna-Maria and Denton, Christopher P and Distler, Oliver},
  title = {Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {11},
  pages = {2099--2106},
  doi = {10.1016/j.ard.2026.08.006}
}
Kostenlos starten →